T-cell engagers (TCEs) are transformative immunotherapies with significant potential in treating hematologic malignancies and solid tumors. However, their real-world safety profiles remain inadequatel
Incidence, absolute risk difference, and relative risk of individual adverse effects for opioids compared to NSAIDs in the propensity-matched cohorts (n = 18,062).
